NeuralStockNeuralStock
HomeResearch mode

DHR

Danaherstock
$230.500.33% today

DHR · 90-day price history

Market cap

$157.6B

P/E

40.0

Div yield

0.71%

Industry

Diagnostics & Research

Exchange

NYSE

Website ↗

Prediction models

All predictions →

Trend follower

Horizon: 1 week

up
Signal strength0.67
Historical accuracy70%
27 predictions · 12mBaseline 65%
How this works

Compares a 10-day vs 50-day moving average. When the short-term average rises above the long-term average, the trend is up.

Not financial advice. Past accuracy does not guarantee future results.

Momentum

Horizon: 1 week

down
Signal strength0.24
Historical accuracy33%
27 predictions · 12mBaseline 65%
How this works

Uses RSI (a gauge of recent buying/selling intensity) and 5-day rate-of-change to judge whether the stock has been pushed too far in one direction.

Not financial advice. Past accuracy does not guarantee future results.

Statistical trend

Horizon: 1 month

up
Signal strength0.50
Historical accuracy100%
10 predictions · 12mBaseline 95%
How this works

Fits a trend line through the last 60 days of prices and measures how far the current price has strayed from it.

Not financial advice. Past accuracy does not guarantee future results.

Multi-factor + news

Horizon: 1 week

AI + NEWS
up
Signal strength0.50
Historical accuracy74%
27 predictions · 12mBaseline 65%

Accuracy reflects technical signals only. News sentiment is live.

How this works

Combines trend (25%), momentum (25%), volume (15%), and AI-analysed news sentiment (35%) from your trusted sources into one score.

Not financial advice. Past accuracy does not guarantee future results.

Bull / Bear thesis

AI analysis
Bull case●

FDA cleared Masimo AI-enabled atrial fibrillation detection system

Major regulatory approval for breakthrough cardiac monitoring technology

Yahoo

Q3 earnings showed margin expansion and operational efficiency gains

Strong financial results with improved profitability

Yahoo

JP Morgan analyst raised price target to $270 showing major bank conviction

Analyst sees significant upside opportunity from current levels

Benzinga
Bear case●

Stock already up 4.29% on FDA approval and earnings

Much of good news already priced into stock price

Price action

FDA approvals often overstated as catalysts - execution matters most

Approval alone doesn't guarantee commercial success

Price action

Analyst target raise reflects past performance, not future visibility

Target may lack visibility into competitive threats

Price action

AI-generated from recent news and price action. Not financial advice. Educational only.

Seasonality

~5y of history

Avg return by month · %

JFMAMJJASOND

This month historically: -3.68% on average, up 20% of 5 years.

Avg return by weekday · %

MonTueWedThuFri

Historical pattern only — seasonality is not a prediction and often breaks.

Recent news

FDA clears Masimo AI system for atrial fibrillation detection

Yahoo · Oct 22

FDA approval opens large market for cardiac monitoring expansion

Danaher Q3 earnings show margin expansion

Yahoo · Oct 22

Operational efficiency driving profitability improvements

JP Morgan raises Danaher price target to $270

Benzinga · Oct 22

Major analyst upgrade reflects confidence in growth trajectory

AI research companion

AI Research Companion

Loading…

Ready to paper trade DHR?

Switch to Portfolio mode to buy and sell with $100k of simulated funds.

Open Portfolio mode →